<DOC>
	<DOCNO>NCT00217386</DOCNO>
	<brief_summary>RATIONALE : Biological therapy , anti-thymocyte globulin etanercept , may stimulate immune system different way stop cancer cell grow . Giving anti-thymocyte globulin together etanercept may kill cancer cell . PURPOSE : This phase II trial study well give anti-thymocyte globulin together etanercept work treat patient myelodysplastic syndrome .</brief_summary>
	<brief_title>Anti-Thymocyte Globulin Etanercept Treating Patients With Myelodysplastic Syndromes</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient low- intermediate-1-risk myelodysplastic syndrome treat anti-thymocyte globulin etanercept . - Correlate ex vivo vitro phenotypic , cytogenetic , functional disease characteristic vivo response patient treat regimen . - Determine parameter associate high probability response non-response patient treat regimen . OUTLINE : This multicenter study . Patients receive anti-thymocyte globulin IV 8 hour day 1-4 . Patients also receive etanercept subcutaneously day 8 , 11 , 15 , 18 . Treatment etanercept repeat every 28 day least 2 course . Patients exhibit hematologic improvement course 2 may receive 2 additional course etanercept absence disease progression unacceptable toxicity . Patients unresponsive disease disease progression course 2 remove study offer treatment . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 30 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis myelodysplastic syndrome ( MDS ) Low intermediate1risk disease , define International Prognostic Scoring System ( IPSS ) criterion , meet 1 follow criterion : Single multilineage cytopenia , define follow : Absolute neutrophil count &lt; 1,500/mm^3 Hemoglobin &lt; 10 g/dL Platelet count &lt; 100,000/mm^3 Transfusion requirement â‰¥ 2 unit pack red blood cell within 8week period Not eligible stem cell transplantation due follow reason : No suitable bone marrow donor available Not eligible transplantation protocol Not willing undergo transplantation No intermediate2 highrisk MDS No chronic myelomonocytic leukemia PATIENT CHARACTERISTICS : Age 18 Performance status Not specify Life expectancy Not specify Hematopoietic See Disease Characteristics Hepatic Not specify Renal Not specify Pulmonary No pneumonia within past 2 week Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No severe disease would preclude study compliance No active severe infection ( e.g. , septicemia ) within past 2 week PRIOR CONCURRENT THERAPY : Biologic therapy More 4 week since prior concurrent hematopoietic growth factor MDS More 4 week since prior immunomodulatory therapy MDS No prior antithymocyte globulin No prior hematopoietic stem cell transplantation No concurrent immunomodulatory therapy MDS Chemotherapy Not specify Endocrine therapy Prednisone &lt; 5 mg/day allow Radiotherapy Not specify Surgery Not specify Other More 4 week since prior concurrent cytotoxic therapy MDS More 4 week since prior experimental therapy MDS No concurrent experimental therapy MDS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
</DOC>